Stanley Laman Group Ltd. Buys 10,088 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Stanley Laman Group Ltd. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 36.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,531 shares of the company’s stock after acquiring an additional 10,088 shares during the period. Stanley Laman Group Ltd.’s holdings in Neurocrine Biosciences were worth $4,324,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mather Group LLC. bought a new stake in shares of Neurocrine Biosciences during the first quarter worth about $26,000. RFP Financial Group LLC increased its position in shares of Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after acquiring an additional 149 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter worth about $28,000. Innealta Capital LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter worth about $30,000. Finally, New Covenant Trust Company N.A. bought a new stake in shares of Neurocrine Biosciences during the first quarter worth about $32,000. 92.59% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Ingrid Delaet sold 273 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total value of $40,322.10. Following the completion of the sale, the insider now owns 6,607 shares of the company’s stock, valued at approximately $975,853.90. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 273 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total transaction of $40,322.10. Following the completion of the sale, the insider now owns 6,607 shares of the company’s stock, valued at $975,853.90. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William H. Rastetter sold 14,250 shares of the stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the sale, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,968 shares of company stock valued at $8,999,632. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $116.78 on Wednesday. The company’s fifty day moving average price is $124.72 and its 200-day moving average price is $134.47. The firm has a market capitalization of $11.75 billion, a price-to-earnings ratio of 32.17 and a beta of 0.36. Neurocrine Biosciences, Inc. has a one year low of $103.63 and a one year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business had revenue of $590.20 million during the quarter, compared to analysts’ expectations of $545.98 million. During the same period last year, the company posted $0.95 EPS. Neurocrine Biosciences’s revenue for the quarter was up 30.4% on a year-over-year basis. As a group, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on NBIX. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 4th. Oppenheimer boosted their price target on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Morgan Stanley boosted their price target on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, July 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.